Skip to Content Facebook Feature Image

Global hydrogen industry reports $75 billion in committed capital but climate targets at stake due to project delays

Business

Global hydrogen industry reports $75 billion in committed capital but climate targets at stake due to project delays
Business

Business

Global hydrogen industry reports $75 billion in committed capital but climate targets at stake due to project delays

2024-09-17 20:23 Last Updated At:20:45

BRUSSELS, Sept. 17, 2024 /PRNewswire/ -- The global clean hydrogen project pipeline is growing and maturing, with a sharp increase in projects reaching final investment decision (FID), according to the Hydrogen Council's latest analysis of more than 1,500 projects worldwide. At the same time, the pace and scale of deployment need to accelerate dramatically to meet global climate goals.

The Hydrogen Insights 2024 report, released today and co-authored by McKinsey & Company, reveals that while the global project pipeline has grown by a factor of seven since 2020 from 228 projects to 1,572 projects, as of May 2024, it has also matured, with a strong focus on advancing projects towards execution. Most notably, clean hydrogen projects that reached FID have also seen a seven-fold increase in committed investment, growing from approximately USD 10 billion across 102 projects in 2020 to some USD 75 billion across 434 projects in 2024.

The most recent data from October 2023 to May 2024 further underscores a clear shift from project planning to implementation. Total announced investments through 2030 have increased by approximately 20% – from USD 570 billion to USD 680 billion. The most notable growth has occurred in the more advanced stages of project development, with investments past FID growing by a remarkable 90%, followed by a 30% increase in front-end engineering design (FEED) stage projects.

This clear shift across the global project pipeline from announcements to implementation is coupled with natural attrition that fosters industry maturation by eliminating less viable projects and prioritising those with the highest potential, a pattern also seen in the early stages of other clean energy industries such as wind and solar.

Jaehoon Chang, President and CEO of Hyundai Motor Company and Co-Chair of the Hydrogen Council, said: "The seven-fold increase in committed capital for hydrogen projects reaching FID over the past four years demonstrates the industry's progress. We are pleased to see the industry walking the talk at this critical transitional moment, as evidenced in the latest Insights report. Moreover, further action is needed to ensure an accessible and affordable hydrogen supply, enabling the widespread adoption of hydrogen."

Despite progress, the hydrogen sector, like other clean energy industries currently, faces macroeconomic headwinds including rising inflation and interest rates, as well as geopolitical tensions affecting energy markets. Sector-specific issues such as regulatory uncertainty and increasing costs for renewable power and electrolysers have led to project delays, particularly for renewable hydrogen projects.

Ivana Jemelkova, CEO of the Hydrogen Council, said: "This report sends a clear message: hydrogen is happening. Now that hydrogen is a reality in the energy transition, it's time to drive significantly more investment by 2030 to meet our mid-century targets. Equipped with concrete lessons learned from the past four years, we must urgently address challenges in key markets and create a more favourable environment for project execution."

Sanjiv Lamba, CEO of Linde and Co-Chair of the Hydrogen Council, said: "Realising hydrogen's full climate and socio-economic potential requires a united effort from governments and industry. With a supportive regulatory framework and targeted incentives, investors will have the certainty they need to move projects to FID – ultimately contributing to achieving global climate targets."

About Hydrogen Insights
Hydrogen Insights is the Hydrogen Council's regularly published perspective on the hydrogen industry's evolution. It summarises the current state of the global hydrogen sector and actual hydrogen deployment. Authored by the Hydrogen Council in collaboration with McKinsey & Company, the report draws on a combination of public information and proprietary data from Hydrogen Council members and represents a collaborative effort to share an objective, holistic, and quantitative perspective on the status of the global hydrogen ecosystem.

About The Hydrogen Council
The Hydrogen Council is a global CEO-led initiative with a united vision and long-term ambition for hydrogen to accelerate the clean energy transition. It brings together a diverse group of 140 companies from 20 countries across Americas, Europe, Africa, the Middle East and Asia Pacific. Spanning the entire value chain, and including large multinationals, innovative start-ups as well as investors, the Council's membership represents some $9 trillion in market capitalization, 6.8 million in FTEs and some $6.4 trillion in revenues.

The Council is committed to unlocking the sustainability potential of clean hydrogen, fostering business and technological innovation as drivers for sustainable growth, creating quality jobs and delivering social value. Using its global reach to promote collaboration between industry, governments, investors, and the civil society, the Council provides insights on and pathways for accelerating the deployment of hydrogen ecosystems around the world. It also supports the development of international safety and sustainability standards, paving the way for the deployment of reliable hydrogen solutions at scale.

To find out more visit www.hydrogencouncil.com and follow us on X @HydrogenCouncil and LinkedIn

Media Enquiries
Joanna Damerell, Communications Manager, Hydrogen Council
Joanna.damerell@hydrogencouncil.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Global hydrogen industry reports $75 billion in committed capital but climate targets at stake due to project delays

Global hydrogen industry reports $75 billion in committed capital but climate targets at stake due to project delays

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Recommended Articles